Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

P. Pronzato, G. Mustacchi, F. Riccardi, A. Turletti, A. Michelotti, C. Natoli, L. Livi, L. Del Mastro, M. Donadio, O. Garrone, M. Giordano, M. De Laurentiis, P. Marchetti, F. Montemurro, E. Romagnoli, S. De Placido, L. Biganzoli, M. Cazzaniga

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)vi32
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - Oct 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this